阿霉素与α-干扰素联合治疗晚期肝细胞癌
Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
作者信息
Kardinal C G, Moertel C G, Wieand H S, Schutt A J, O'Connell M J, Wright K, Wiesenfeld M, Tschetter L K, Krook J E
机构信息
Alton Ochsner Medical Foundation Community Clinical Oncology Program (CCOP), New Orleans, Louisiana.
出版信息
Cancer. 1993 Apr 1;71(7):2187-90. doi: 10.1002/1097-0142(19930401)71:7<2187::aid-cncr2820710704>3.0.co;2-j.
BACKGROUND
Modest activity for doxorubicin has been detected repeatedly for the therapy of advanced hepatocellular carcinoma. Variable activity in this disease also has been documented for alpha-interferon. Preclinical data indicated the possibility that alpha-interferon could enhance or add to the cytotoxic effect of doxorubicin.
METHODS
The authors evaluated the use of alpha-interferon at a dose of 12 x 10(6) units/m2/day for 5 days given by intramuscular injection plus doxorubicin 25-40 mg/m2 given intravenously on day 3 (both repeated every 4 weeks) for the treatment of advanced hepatocellular carcinoma.
RESULTS
Among 31 eligible patients treated, there was only one instance of objective tumor regression. The median survival for all patients was 10 months. Both hematologic and nonhematologic toxicity were significant but tolerable to the patients.
CONCLUSIONS
The 3% response rate indicated that, by the method used, the addition of alpha-interferon to doxorubicin does not improve the clinical effectiveness. This combination cannot be recommended for further study.
背景
多柔比星治疗晚期肝细胞癌的疗效已被反复证实疗效一般。α干扰素治疗该疾病的疗效也存在差异。临床前数据表明α干扰素可能增强多柔比星的细胞毒性作用或增加其细胞毒性。
方法
作者评估了α干扰素（剂量为12×10⁶单位/m²/天，肌内注射，共5天）联合多柔比星（25 - 40mg/m²，静脉注射，第3天给药）（两者均每4周重复一次）治疗晚期肝细胞癌的效果。
结果
在31例符合条件的患者中，仅1例出现客观肿瘤消退。所有患者的中位生存期为10个月。血液学和非血液学毒性均较显著，但患者可耐受。
结论
3%的缓解率表明，采用该方法，α干扰素联合多柔比星并不能提高临床疗效。不推荐对该联合方案进行进一步研究。
Zotero 插件